{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T06:21:49Z","timestamp":1782627709348,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071410"],"award-info":[{"award-number":["82071410"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471426"],"award-info":[{"award-number":["82471426"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3501303"],"award-info":[{"award-number":["2022YFC3501303"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3501305"],"award-info":[{"award-number":["2022YFC3501305"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clim.2025.110657","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:29:54Z","timestamp":1765931394000},"page":"110657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis"],"prefix":"10.1016","volume":"283","author":[{"given":"Hui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huahua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenji","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liewen","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clim.2025.110657_bb0005","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated myasthenia gravis","volume":"28","author":"\u00c1lvarez-Velasco","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2025.110657_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102337","article-title":"Risk factors associated with myasthenia gravis in thymoma patients: the potential role of thymic germinal centers","volume":"106","author":"Lefeuvre","year":"2020","journal-title":"J. Autoimmun."},{"issue":"6","key":"10.1016\/j.clim.2025.110657_bb0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of Thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.clim.2025.110657_bb0020","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.hlc.2013.02.010","article-title":"Surgery of myasthenia gravis associated or not with thymoma: a retrospective study of 43 cases","volume":"22","author":"El Hammoumi","year":"2013","journal-title":"Heart Lung Circ."},{"issue":"4","key":"10.1016\/j.clim.2025.110657_bb0025","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/ejcts\/ezx163","article-title":"Risk factors of myasthenic crisis after thymectomy for thymoma patients with myasthenia gravis","volume":"52","author":"Xue","year":"2017","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"5","key":"10.1016\/j.clim.2025.110657_bb0030","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/1759-7714.13396","article-title":"Surgical effect and prognostic factors of myasthenia gravis with thymomas","volume":"11","author":"Tian","year":"2020","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.clim.2025.110657_bb0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1245\/s10434-011-1896-8","article-title":"Different characteristics of thymomas with and without myasthenia gravis","volume":"19","author":"Lei","year":"2012","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.clim.2025.110657_bb0040","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ana.25087","article-title":"A clinical predictive score for postoperative myasthenic crisis","volume":"82","author":"Kanai","year":"2017","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.clim.2025.110657_bb0045","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jtcvs.2003.07.036","article-title":"Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis","volume":"127","author":"Watanabe","year":"2004","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"3","key":"10.1016\/j.clim.2025.110657_bb0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis","volume":"96","author":"Sanders","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.clim.2025.110657_bb0055","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2025.110657_bb0060","first-page":"17","article-title":"Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study","author":"Jin","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.clim.2025.110657_bb0065","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","article-title":"Eculizumab versus rituximab in generalised myasthenia gravis","volume":"93","author":"Nelke","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.clim.2025.110657_bb0070","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2025.110657_bb0075","series-title":"Soliris (Eculizumab) Injectable IV Approval Letter","author":"U.S. Food & Drug Administration","year":"2007"},{"key":"10.1016\/j.clim.2025.110657_bb0080","first-page":"14","article-title":"Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance","author":"Murai","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"11","key":"10.1016\/j.clim.2025.110657_bb0085","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1007\/s00415-022-11222-8","article-title":"Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report","volume":"269","author":"Strano","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2025.110657_bb0090","first-page":"13","article-title":"Eculizumab as a promising treatment in thymoma-associated myasthenia gravis","author":"V\u00e9lez-Santamar\u00eda","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"12","key":"10.1016\/j.clim.2025.110657_bb0095","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jtho.2023.08.024","article-title":"The International Association for the Study of Lung Cancer Thymic epithelial tumor staging project: proposal for the T component for the forthcoming (ninth) edition of the TNM classification of malignant tumors","volume":"18","author":"Okumura","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.clim.2025.110657_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann. Thorac. Surg."},{"issue":"1","key":"10.1016\/j.clim.2025.110657_bb0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ene.14052","article-title":"Frequency and features of myasthenia gravis developing after thymectomy","volume":"27","author":"Uzawa","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2025.110657_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102895","article-title":"Poor responses and adverse outcomes of myasthenia gravis after thymectomy: predicting factors and immunological implications","volume":"132","author":"Chen","year":"2022","journal-title":"J. Autoimmun."},{"issue":"48","key":"10.1016\/j.clim.2025.110657_bb0115","doi-asserted-by":"crossref","first-page":"30649","DOI":"10.1073\/pnas.2007206117","article-title":"Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis","volume":"117","author":"Jiang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.clim.2025.110657_bb0120","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/acn3.51055","article-title":"Risk of incident autoimmune diseases in patients with thymectomy","volume":"7","author":"Lin","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.clim.2025.110657_bb0125","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Maria Elena Farrugia","year":"2020","journal-title":"Front. Neurol."},{"issue":"25","key":"10.1016\/j.clim.2025.110657_bb0130","article-title":"Perioperative safety and efficacy of Efgartigimod for Thymoma-associated myasthenia gravis: a prospective, multicenter, phase II clinical trial","volume":"S1556-0864","author":"Wang","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.clim.2025.110657_bb0135","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mus.27973","article-title":"Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies","volume":"68","author":"Ozawa","year":"2023","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.clim.2025.110657_bb0140","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/0002-8703(89)90012-4","article-title":"Effects of diltiazem on phosphate metabolism in ischemic and reperfused myocardium using phosphorus31 nuclear magnetic resonance spectroscopy in vivo","volume":"118","author":"Kavanaugh","year":"1989","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.clim.2025.110657_bb0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clim.2025.110657_bb0150","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/TP.0000000000004646","article-title":"Cellular Immunobiology and molecular mechanisms in Alloimmunity-pathways of immunosuppression","volume":"108","author":"Schrezenmeier","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2025.110657_bb0155","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2017.06.006","article-title":"Small molecules to the rescue: inhibition of cytokine signaling in immune-mediated diseases","volume":"85","author":"Gadina","year":"2017","journal-title":"J. Autoimmun."},{"issue":"17","key":"10.1016\/j.clim.2025.110657_bb0160","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2165\/11208300-000000000-00000","article-title":"Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria","volume":"71","author":"McKeage","year":"2011","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.clim.2025.110657_bb0165","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.clim.2025.110657_bb0170","article-title":"The role of complement in the pathogenesis and treatment of myasthenia gravis","volume":"14","author":"Salazar","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.clim.2025.110657_bb0175","unstructured":"R S Liu,E G Yao,Y L Nie. Chin Med J (Engl). Treatment of acute leukemia with rifampin and low dose harringtonine. Anal. 14 Cases1989;102(9):695\u20137."},{"issue":"1","key":"10.1016\/j.clim.2025.110657_bb0180","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1510\/icvts.2005.116616","article-title":"Thymoma is associated with relapse of symptoms after transsternal thymectomy for myasthenia gravis","volume":"5","author":"Hsu","year":"2006","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"issue":"8","key":"10.1016\/j.clim.2025.110657_bb0185","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/ene.15362","article-title":"Short-term and sustained clinical response following thymectomy in patients with myasthenia gravis","volume":"29","author":"Rath","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2025.110657_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1562419","article-title":"Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience","volume":"16","author":"Marini","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2025.110657_bb0195","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00415-025-13127-8","article-title":"Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience","volume":"272","author":"Rossini","year":"2025","journal-title":"J. Neurol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625002323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625002323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:27:36Z","timestamp":1769128056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625002323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"alternative-id":["S1521661625002323"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110657","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110657"}}